Get started
Author

James B. Drew

Comparison of three nonradioisotopic polymerase chain reaction-based methods for detection of human immunodeficiency virus type 1
1992 · A J Whetsell, J B Drew, et al. · Journal of Clinical Microbiology · 78
Establishment of a quality assurance program for human immunodeficiency virus type 1 DNA polymerase chain reaction assays by the AIDS Clinical Trials Group. ACTG PCR Working Group, and the ACTG PCR Virology Laboratories
1993 · J B Jackson, J Drew, et al. · Journal of Clinical Microbiology · 69
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL
2021 · Peter Martin, Nancy L. Bartlett, et al. · Blood · 38
PDF
Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study
2022 · Catherine Thieblemont, Javier Munoz, et al. · Blood · 15
Cholecystokinin Antagonist Prevents Hyperamylasemia and Improves Pancreatic Exocrine Function in Cerulein-Induced Acute Pancreatitis
1990 · Kenric M. Murayama, James B. Drew, et al. · Pancreas · 15
Bile Exclusion from the Gut Exacerbates Acute Pancreatitis Caused by Pancreatic Duct Obstruction in Rats
1991 · Kenric M. Murayama, James B. Drew, et al. · Pancreas · 12
Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.
2025 · Salomon Manier, Enrique M. Ocio, et al. · Journal of Clinical Oncology · 5
Phase I/II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL.
2020 · Neha Mehta-Shah, Julio C. Chavez, et al. · Journal of Clinical Oncology · 4
Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)
2018 · Peter Martin, Nancy L. Bartlett, et al. · Blood · 4
Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial.
2025 · Paula Rodríguez-Otero, Sosana Delimpasi, et al. · Journal of Clinical Oncology · 1
Linvoseltamab (LINVO) + Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Initial Results from the LINKER-MM2 Trial
2025 · Salomon Manier, Enrique Ocio, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 11
Citation count: 241
H-index: 6
I10-index: 6
Year
Topic
Type